Page 5
Swiss “Acino Pharma” acquired
Ukrainian “Pharma Start”
On Oct 1, 2015, Swiss
pharmaceutical company
“Acino Pharma” finished the
acquisition of the 10 th biggest
Ukrainian pharm-producer (25 th
at Ukrainian pharma market)
“Pharma Start”. The acquisition
was held under the “Acino’s”
development strategy at the
emerging markets, which will
allow the company to increase
its turnover for more than three
times – from € 300 mio to € 1 bn
– during five years.
“Acino” has acquired 100% of
“Pharma Start” assets. The
amount of the transaction is
undisclosed.
The acquisition will allow “Acino”
to produce drugs with the
use of advanced technologies
at affordable prices. At time,
“Acino’s” four products for the
treatment of cardiovascular
diseases are at different stages
of obtaining permits to enter the
Ukrainian market. The company
also plans to bring a transdermal
patch “Rivastigmine” for the
treatment of Alzheimer’s disease
to Ukrainian market.
At the first stage, the products
will be manufactured under the
“Acino Pharma Start” brand. In
two years, the company plans to
move to “Acino” brand.
“The international pharm industry
is still looking at Ukrainian market
very carefully,” the CEO of “Acino
Pharma” Jostein Davidsen said.
“The bright future will not come
immediately, but we believe in
it, that is why we acquired the
company from Ukraine. I believe
that the investments will return
in Ukraine. And what do we do
now will be a signal for foreign
investors”.
“Pharma Start’s” portfolio
consists of 35 drugs, specializing
on CNS, cardio and OTC
segments. The company covers
the whole sup